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Abstract
Introduction: The aim of this prospective, randomized, controlled, double-blind study was to evaluate the effects
of tiludronate (TLN), a bisphosphonate, on structural, biochemical and molecular changes and function in an
experimental dog model of osteoarthritis (OA).
Methods: Baseline values were established the week preceding surgical transection of the right cranial/anterior
cruciate ligament, with eight dogs serving as OA placebo controls and eight others receiving four TLN injections
(2 mg/kg subcutaneously) at two-week intervals starting the day of surgery for eight weeks. At baseline, Week 4
and Week 8, the functional outcome was evaluated using kinetic gait analysis, telemetered locomotor actimetry
and video-automated behaviour capture. Pain impairment was assessed using a composite numerical rating scale
(NRS), a visual analog scale, and electrodermal activity (EDA). At necropsy (Week 8), macroscopic and
histomorphological analyses of synovium, cartilage and subchondral bone of the femoral condyles and tibial
plateaus were assessed. Immunohistochemistry of cartilage (matrix metalloproteinase (MMP)-1, MMP-13, and a
disintegrin and metalloproteinase domain with thrombospondin motifs (ADAMTS5)) and subchondral bone
(cathepsin K) was performed. Synovial fluid was analyzed for inflammatory (PGE2 and nitrite/nitrate levels)
biomarkers. Statistical analyses (mixed and generalized linear models) were performed with an a-threshold of 0.05.
Results: A better functional outcome was observed in TLN dogs than OA placebo controls. Hence, TLN dogs had
lower gait disability (P = 0.04 at Week 8) and NRS score (P = 0.03, group effect), and demonstrated behaviours of
painless condition with the video-capture (P < 0.04). Dogs treated with TLN demonstrated a trend toward
improved actimetry and less pain according to EDA. Macroscopically, both groups had similar level of
morphometric lesions, TLN-treated dogs having less joint effusion (P = 0.01), reduced synovial fluid levels of PGE2
(P = 0.02), nitrites/nitrates (P = 0.01), lower synovitis score (P < 0.01) and a greater subchondral bone surface (P <
0.01). Immunohistochemical staining revealed lower levels in TLN-treated dogs of MMP-13 (P = 0.02), ADAMTS5
(P = 0.02) in cartilage and cathepsin K (P = 0.02) in subchondral bone.
Conclusion: Tiludronate treatment demonstrated a positive effect on gait disability and joint symptoms. This is
likely related to the positive influence of the treatment at improving some OA structural changes and reducing the
synthesis of catabolic and inflammatory mediators.
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Osteoarthritis (OA) is among the most common muscu-
loskeletal conditions [1]. This disease leads to functional
disability and a reduced quality of life [2]. The abnormal
biomechanics are believed to be among the major risk fac-
tors of disease progression and joint tissue damage [3].
Subchondral bone turnover is a well-defined component
of OA [4]. The interactive process between articular carti-
lage and subchondral bone is complex and not yet fully
understood. Yet, as these tissues are intimately related
components of the joint, treatment to limit excessive bone
remodelling is believed to have a possible positive effect
on the global evolution of OA structural changes. Indeed,
bone anti-resorptive agents have been shown to limit the
development of OA structural changes in a number of
experimental models [5]. For instance, inhibition of bone
remodelling by licofelone [6] and calcitonin [7] in the
experimentally transected canine anterior cruciate liga-
ment (ACL) model of OA was shown to reduce cartilage
lesions. Similar evidence also emerged from the work
done on oestrogen replacement therapy in ovariectomized
monkeys [8].
Bisphosphonates (BPs) are a well-known class of mole-
cules that contain two phosphonate groups attached to a
single carbon atom, forming a “P-C-P” structure. The anti-
resorptive effects of these biochemical analogs of inorganic
pyrophosphate have been demonstrated in skeletal dis-
eases where excessive bone resorption is present [9]. The
anion of tiludronic acid (tiludronate, TLN) is a non-nitro-
gen-containing BP that acts on bone through mechanisms
that involve induction of osteoclast apoptosis and preven-
tion of extracellular degradation and of pro-inflammatory
cytotrafficking [10], leading to decreased mineralized
matrix resorption. This drug is recommended for skeletal
disorders characterized by an increased and abnormal
bone remodelling, such as Paget’s disease, and is currently
t h eo n l yB Pa p p r o v e di nv e t e r i n a r ym e d i c i n et oa l l e v i a t e
clinical signs of an OA condition in horses [11]. There is
yet insufficient data to claim a potentially beneficial effect
of TLN on the pathological changes encountered in OA.
A recent study demonstrated that pre-emptive chronic
zoledronate (a nitrogenous BP) treatment increases bone
mineral density, and is chondroprotective and analgesic
in both chemical (mono-iodo-acetate, MIA) and surgical
experimental models of painful joint degeneration in the
rat [12]. The authors showed that osteoclast-mediated
resorption of cartilage at the subchondral bone/cartilage
interface is an early initiating event in the pathobiology
of the MIA model as opposed to chondrocyte death and
subsequent mechanical erosion of the articular surface.
Pre-emptive zoledronate fully inhibited the subchondral
bone/cartilage molecular cross-talk [4,13] and/or the BP
could have had a direct analgesic effect. This provided
further rationale to test the potency of TLN at improving
functional disability and structural changes in the canine
ACL model of OA.
While BPs [14,15] and other antiresorptive agents
[5-7,16] have shown promise, mostly structural effects
(inhibition of cartilage degeneration [12,14], prevention
of osteophytes [14] and reduction in bone marker turn-
over [15]) in animal models of OA with pre-emptive
treatment, clinical results in knee OA patients have been
disappointing, for example, with risedronate [17]. In OA,
sclerosis of the subchondral bone is preceded by its
resorption in the early phase [4,13,18]. This bone remo-
delling has also been characterized as bone marrow
lesions (BML) on magnetic resonance imaging (MRI),
and could also be perceived as an adaptation to changes
in the biomechanics (maintaining intramedullary home-
ostasis [19]) or in an attempt to repair microdamages
[18]. Therefore, bone remodelling has been associated
with redistribution of mechanical stress [19], and the
hypothesis has been advanced that to counteract it could
prevent the repair of naturally occurring bone microdam-
age, thus increasing the susceptibility to crack initiation
[20]. Moreover, in the ACL transection canine OA
model, an experimental BP was demonstrated to be effec-
tive at reducing the turnover of cancellous subchondral
bone, but ineffective at preventing osteophyte formation
or pathologic changes of OA in the overlying cartilage
[21]. Rather, a decrease in proteoglycan synthesis was
observed, suggestive of impairment in the hypertrophic
repair process. In contrast, chondroprotection was
denoted in cruciate-deficient rats under BP treatment
[12,14] in parallel to a decrease in the expression of
degradative enzymes [14] as well as of biochemical mar-
kers of cartilage degradation in human beings [17]. Also,
in these studies stating a limited efficacy for BP treatment
[17,21], it has to be noted that one main limitation to
i n f e r e n c ew a st h er e l a t i v e l ym i l dd e g r e eo fO Ai nt h e
control animals [21] as well as the absence of OA radio-
graphic signs progression in placebo subjects [17].
ACL transection in dogs generates abnormal biome-
chanical forces and metabolic pathways that initiate
structural changes on morphometry and histology [5], as
well as on imaging [22,23], mimicking those seen in natu-
rally occurring OA. This model is additionally acknowl-
edged to induce significant chronic gait disability and
functional impairment [24,25]. The canine ACL model of
OA is valuable for assessing the evolution of functional
outcomes in response to treatment [5]. In the present
study, we hypothesized that the bone anti-resorptive
action of TLN might curb the development of structural
and functional joint lesions associated with ACL transec-
tion. We used a set of complementary tools to relate pain
and functional outcomes in parallel to joint structural,
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evaluation of the effect of TLN on limb loading, pain/
stress sensation, activity level and behaviours related to
canine experimental OA conditions.
Materials and methods
In this randomized, double-blind, placebo-controlled
study with a parallel design (Figure 1), dogs were ran-
domly allocated to two treatment groups of eight dogs
each, stratified by body weight and gender. Investigators
were blinded to group allocation, as well as treatment.
The study protocol was approved by the institutional
animal care and use committee (RECH-1268) and con-
ducted in accordance with the Canadian Council on
Animal Care guidelines.
Animals
Sixteen adult crossbred dogs (aged two to three years),
with an average (SD) body weight of 26 (3.3) kg were
used in this study. They were individually housed in gal-
vanized steel cages (1 m (width) × 1.75 m (length) × 2.4
m (height)) fitted with automatic waterers. Dogs were
included in the study after complete physical and mus-
culoskeletal evaluation by a veterinarian, and haematolo-
gical and biochemical analyses. Food (approximately 450
g Hill’s Pet Nutrition Science Diet Canine Adult Origi-
nal mixed with Harlan Teklab Global 27% Protein Dog
Diet) was given once daily and removed overnight. Tap
water (purified by filtration) was provided to the animals
ad libitum.
Surgical transection of the anterior cruciate ligament
(ACL)
After evaluation of baseline pain and functional outcome
levels, all anaesthetized dogs were subjected to ACL
transection of the right knee as previously described [26].
Under pre-emptive (transdermal fentanyl 50 or 75 μg/h,
Duragesic
®; Janssen Ortho, Markham, ON, Canada) and
multimodal (intra-articular block combined with opioid
administration) analgesia, the tibial edge was located with
the thumb and index finger, followed by a medial sagittal
skin incision (30 mm). The subcutaneous tissues were
dissected, and a medial arthrotomy was performed, distal
to the patella and parallel to the patellar ligament. A
retractor was inserted to view the ACL to be sectioned,
the completeness of which was verified by obtaining a
large drawer motion in both flexion and extension. The
capsule and the retinaculum were sutured in a simple
continuous pattern. Bupivacaine (Marcaïne
® 0.5%; Hos-
pira, St-Laurent, QC, Canada) was injected (5 to 8 mL) in
the capsule as an intra-articular block. Finally, the subcu-
taneous tissues were sutured, followed by intra-dermal
and skin sutures.
Treatment
One group was treated with 2 mg/kg of disodium TLN
dissolved in a mannitol solution (CEVA Santé Animale,
Libourne, France). The OA control group received only
the vehicle solution (CEVA Santé Animale). Both treat-
ments (0.2 mL/kg) were injected subcutaneously (SC),
starting on the day of ACL transection, and repeated
Figure 1 Schematic representation of the study design.
Moreau et al. Arthritis Research & Therapy 2011, 13:R98
http://arthritis-research.com/content/13/3/R98
Page 3 of 13every two weeks up to the end of the follow-up (total of
four administrations). The dose level of TLN was
selected by the Sponsor based on preliminary studies in
rats [27] and using an allometric scale-up to the weight
of dogs.
Pain and functional evaluations
Gait analysis
In dogs, the use of a pressure-sensing walkway device
acquires limb loading and is defined as a quantitative
measurement of gait function [25]. Gait analysis was per-
formed at baseline, Week 4 and Week 8 using the podo-
barometric recording device (Walkway
® System; Tekscan
Inc, Boston, MA, USA) [25,28]. For the right (ACL-defi-
cient) hind limb, the peak vertical force (PVF) was
acquired at a trotting gait velocity ranging from 1.9 to 2.2
meters/second. Velocity and acceleration (± 0.5 meter
per second
2) was ensured using a set of three photoelec-
tric cells specially designed for this podobarometric
device (LACIME; École de Technologie Supérieure, Mon-
tréal, QC, Canada). The gait acquisition window was
three seconds with a sampling rate set at 44 hertz, produ-
cing a total of 132 frames. Raw PVF (Kg) data from the
first five valid trials were obtained for each dog and later
used for statistical purposes using body weight as a cov-
ariate [25]. Data were expressed as percentage of body
weight (%BW).
Pain scoring systems
The lameness and pain of treated and control OA dogs
were evaluated using previously developed scoring sys-
tems, and included a visual analog scale (VAS) [29] and
a composite numerical rating scale (NRS) [30]. The pain
scores were obtained at baseline, Week 4 and Week 8
by the same technician [29] with a 100 mm VAS scale,
coding from 0 ("no pain”) to 100 ("pain intensity could
not be worse”). The composite NRS, which was scored
by the same veterinarian throughout the study, includes
the following seven criteria: Global assessment (score 0
to 4); Evaluation of lameness while the dog is standing
up (score 0 to 4), walking (score 0 to 4) and trotting
(score 0 to 4); Willingness to hold up contralateral limb
(score 0 to 4); Evaluation of response to palpation (score
0 to 4); Evaluation of response to flexion and extension
(score 0 to 4). Inter- and intra-observer reliability of
both VAS and NRS were tested and found to be highly
satisfying (Spearman correlation, rho >0.72, P < 0.001).
Electrodermal activity (EDA)
Changes in skin conductance response (EDA) resulting
from sympathetic neuronal activity [31] has recently
been validated in the canine ACL model of OA as a
measurement of stress or pain that is strongly associated
with functional outcomes [30]. The EDA was recorded
at baseline, Week 4 and Week 8 using a Pain Gauge
®
(PHIS, Inc., Dublin, OH, USA) system, which grades the
signal intensity on a scale of 0 to 10, with 10 being the
most painful. The device was placed for two seconds on
the right palmar paw (dry and non-clipped).
Video-automated behaviour analysis
The computer-assisted behavioural analysis (The Obser-
ver v5.0.31; Noldus Information Technology, Inc., Lees-
burg, VA, USA) allowed the assessment of behavioural
changes suggestive of a pain-related condition [32]. The
capture of behavioural changes in terms of body posi-
tions and motor activities allows a non-invasive monitor-
ing of pain-related functional disability and discomfort.
Recording was performed in the outdoor runs where the
dogs exercised for two consecutive hours, at baseline and
at Week 8. The resulting ethogram included the follow-
ing eight classes of behaviour: location in the run, body
position, facial expression, vocalization, tail position, self-
care, motor activity and dog interaction. The analysis of
behaviour occurrence was done following the manufac-
turer’s recommendations.
Telemetered locomotor actimetry
Acceleration-based monitoring of frequency, intensity,
and duration of physical activities is a valid objective tool
to monitor pain-related functional disability [30,33]. At
baseline, Week 4 and Week 8, locomotor actimetry was
monitored continuously for 24 hours with an electronic
chip (Actical
®; Bio-Lynx Scientific Equipment, Inc., Mon-
treal, QC, Canada) that was placed inside a protective
neck collar. During this time, all dogs followed the same
daily routine to ensure consistency. The cumulative loco-
motor activity was recorded over two minutes, thus pro-
viding 720 measurements over 24 hours. The height of
peaks for each recording was scaled in arbitrary units
from 0 to ∞ to quantify the intensity of locomotor acti-
metry [30]. Comparison of actimetry with simultaneous
video-automated recordings allowed the threshold to be
set between active and inactive motions at 30 units. Data
were then expressed as daily averaged total intensity
(considering all counts, DATI), and daily averaged active
intensity (considering only counts higher than 30 in
intensity as active counts, DAAI).
Macroscopic grading
At the end of the study, the dogs were euthanized under
sedation with barbiturate overdose. The right knee of
each dog was placed on crushed ice and dissected for
quantification of gross morphological changes. Two
independent observers who were blinded to treatment
group allocation graded the findings with a consensual
value [25,26,34].
Cartilage
Macroscopic lesion areas at the cartilage surface on the
femoral condyles and tibial plateaus were measured (in
mm
2) with an electronic digital calliper (Digimatic Cali-
per model No. 2071M; Mitutoyo Corporation, Kawasaki,
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ranging between 0 (a normal surface) and 4 (erosion
extending to the subchondral bone).
Osteophytes
When present, the degree of osteophyte formation was
quantified by measuring the maximal width (mm) of the
spurs on the medial and lateral femoral condyles as pre-
viously described [26]. For statistical purposes, data were
evaluated separately for lateral and medial osteophytes and
also summated for the entire condyles.
Histological grading of cartilage and synovial membrane
Cartilage
Full thickness cartilage sections were removed from the
weight-bearing lesional areas of the femoral condyles and
tibial plateaus allowing standardization of sampling [25].
Histological evaluation was performed on sagittal sections
of cartilage from each femoral condyle and tibial plateau
specimen [25,26,34]. After dissection, specimens were
fixed in 4% buffered formalin and embedded in paraffin.
Serial sections (5 μm) were stained with haematoxylin/
Fast green and Safranin-O. The severity of cartilage
pathology was graded by two independent observers using
the OsteoArthritis Research Society International histo-
pathology scoring system [35]. For statistical purposes,
data from both observers were considered for the lateral
and medial part of the condyles and plateaus as well as for
the entire joint.
Synovial membrane
Synovial membrane was removed and processed as
described above, but stained with haematoxylin/eosin.
Two independent observers evaluated two specimens. The
severity of synovitis was graded on a scale of 0 to 10,
including four histological criteria as previously described
[34]: synovial cell hyperplasia (scale 0 to 2), villous hyper-
plasia (0 to 3) and mononuclear (0 to 4) and polymorpho-
nuclear (0 to 1) cell infiltration; 0 indicates normal
structure. For statistical purposes, data from both obser-
vers and both specimens were considered.
Analysis of synovial fluid
At euthanasia, samples of synovial fluid were collected,
measured, and then centrifuged and frozen (-80°C).
Prostaglandin (PG) E2 assay
The amount of PGE2 (ng/knee) was determined using a
commercially available Enzyme ImmunoAssay (Cayman
Chemicals, Ann Arbor, MI, USA) according to the man-
ufacturer’s instructions, the limit of detection being 15
pg/mL. The concentration measurements were done in
duplicate and the values averaged.
Nitrites and nitrates (NOx) assay
Nitrite and nitrate levels (nmol/knee) were determined
by chemiluminescence [36] using a NO Analyzer (280i
®,
Sievers Instruments, Boulder, CO, USA), according to
the manufacturer’s instructions. Briefly, 0.025 mL of the
supernatant was injected into the microreaction purge
vessel of the analyzer. The purge vessel contained 5 mL
of vanadium solution heated at 95°C. The instrument
measures NOx on a gas-phase chemiluminescent reac-
tion between NO and ozone. Each sample was analyzed
in duplicate and values averaged.
Immunohistochemistry
Full thickness specimens from the tibial plateaus and
femoral condyles were processed for immunohistochem-
ical analysis, as previously described [6,26,34]. After the
slides were incubated with a blocking serum (Vectastain
ABC kit; Vector Laboratories, Inc., Burlingame, CA,
USA) for 60 minutes, they were blotted and then overlaid
with the primary antibody against the following: matrix
metalloproteinase (MMP)-1 (1/40 dilution, mouse mono-
clonal; Calbiochem ref. #444209; EMD Biosciences,
Darmstadt, Germany), MMP-13 (1/6, goat polyclonal
antibody; R&D Systems, Minneapolis, MN, USA), a disin-
tegrin and metalloproteinase domain with thrombospon-
din motifs (ADAMTS)5 (1/50, rabbit polyclonal;
Cedarlane ref. #CL1-ADAMTS5; Hornby, ON, Canada),
and cathepsin K (1/200, goat polyclonal; Santa Cruz Bio-
technology ref. #sc-6506; Santa Cruz, CA, USA) for 18
hours at 4°C in a humidified chamber.
Each slide was stained using the avidin-biotin complex
method (Vectastain ABC kit), and incubated in the pre-
sence of the biotin-conjugated secondary antibody for 45
minutes at room temperature followed by the addition of
the avidin-biotin-peroxidase complex for 45 minutes.
The slides were counterstained with eosin. Determination
of the staining specificity as well as the immunohisto-
chemistry analysis (three fields from each specimen
examined) was done as previously described [6,26,34].
Each section was examined under a light microscope
(Leitz Orthoplan; Leica, Inc., St. Laurent, QC, Canada)
and photographed using a CoolSNAP of Photometrics
camera (Roper Scientific, Rochester, NY, USA). The
results are expressed as the percentage of cells staining
positive for the antigen (MMP-1, -13 and ADAMTS5) in
the upper zone of cartilage with the maximum value
being 100%. Similarly, on decalcified specimens (see the
Histomorphometry section), the number of cathepsin K
positive cells was quantified in the subchondral bone, as
previously described [6]. For statistical purposes, data
from all specimens (tibial plateaus and femoral condyles)
and all fields were considered. The data presented are the
average of the three fields.
Histomorphometry
Specimens of full-thickness sections of the articular carti-
lage including the subchondral bone from the lesional
area of the medial tibial plateau of all dogs were placed in
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(vol/vol) formic acid in formalin for 12 hours and
embedded in paraffin, as previously described [6].
Subchondral bone
Sections (5 μm) of each specimen were subjected to Fast
green/Safranin-O staining. A Leitz Diaplan DMLS
®
microscope (Leica Microsystems, Wetzlar, Germany)
connected to a personal computer (Pentium IV, using
Image J software, v1.27; NIH, Bethesda, MD, USA and
OSTEO II Image Analysis software; Bioquant, Nashville,
TN, USA) was used to conduct the subchondral bone
histomorphometry, which was performed as previously
described [6,26]. Measurement of the bone surface
(mm
2), trabecular thickness (μm) and trabecular separa-
tion (mm) was done according to standard conventions
[6].
Calcified cartilage
The calcified cartilage histomorphometry was done for
each specimen, as previously described [6]. The surface
(mm
2) of the calcified cartilage was calculated using the
computerized program.
Statistical analysis
Linear mixed models for repeated measures were used to
evaluate the effect of Time, Group and Time per Group
interaction for PVF, EDA and actimetry recording using
compound symmetry covariance structures. Trials (PVF)
and dogs were random effects nested in treatment
groups. At each time point, a group’s least squares means
were compared with appropriate Tukey or Bonferroni
adjustments. To evaluate the effect of Time, Group and
Time per Group interaction on VAS and summated
NRS, repeated-measures generalized linear models with
generalized estimating equations were used, where data
were assumed to distribute under the Log-Gamma, and
the overdispersed Poisson probability functions, respec-
tively. For the latter variable, the variance scale factor
was estimated by Pearson’s chi-square/Degree of free-
dom. Best working matrix was determined to be first-
o r d e ra u t o r e g r e s s i v ef o l l o w i n gt h es t r a t e g yp r o p o s e db y
Littell et al. [37].
For the video-automated behaviour analysis, the occur-
rence of each specific event was cumulated. Frequencies
were then compared between TLN and placebo control
groups using a negative binomial regression model with
baseline occurrence as covariate. Values were expressed
as changes in the frequency of a given behaviour accord-
ing to the tested group.
Synovial fluid volume, levels of inflammatory factors,
cellular ratios and structure measurements were tested
between groups using linear mixed models. Where appro-
priate, specimen or fields were used as random effects
nested in treatment groups. Data presented as scores or
counts were tested using a generalized linear model under
the logistic polytomous distribution function using the
proportional odds assumption, or the over-dispersed Pois-
son probability functions when scores were summated.
Where appropriate, specimen or observers were used as
random effects nested in treatment groups. Alpha thresh-
old for significance was set at 5%. Data are presented as
mean (SD). Statistical analyses were done using SPSS Sta-
tistics software v17.0 (SPSS Inc, Chicago, IL, USA) and
SAS software, v9.1, (SAS Institute Inc, Cary, NC, USA).
Results
Pain and functional outcomes
The temporal evolution of PVF recording implied severe
gait disability denoted by decreasing values over time (P <
0.01) (Figure 2, Table 1). Treatment interacted with the
temporal recording of PVF (P < 0.01). The TLN treatment
Figure 2 Kinetic gait analysis. Peak vertical force (mean (standard
deviation)) recorded before (baseline) and four and eight weeks
after anterior cruciate ligament transection in dogs. Line plots
representation includes respective values for A) placebo-control and
B) tiludronate treated dogs. There was a significant time effect (P <
0.01), a group effect (P = 0.05) and a time per group interaction (P
< 0.01) with PVF value reaching 35% higher in tiludronate than in
placebo-control at Week 8 (P = 0.04).
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limb impairment compared to the placebo control over
time (P = 0.05), reaching PVF values 35% higher at Week
8( P = 0.04).
Assessment provided by VAS and NRS (Table 1) echoed
the temporal evolution observed with gait analysis (PVF):
After surgery, both methods detected a worsening of the
dogs’ condition. Assessment provided by VAS revealed an
improvement from Week 4 to Week 8 (P < 0.01) in both
groups, without the presence of an interaction of treat-
ment on VAS recording. Of note, TLN dogs tended to
have lower VAS grades than controls (P = 0.06). With
respect to NRS, groups were not significantly improved
from Week 4 to Week 8 and no interaction was denoted.
However, there was a significant group effect (P = 0.03) on
the overall NRS recorded post surgery.
According to EDA values (Table 1), the level of pain/
stress sensation recorded after surgery did not change
over time in the TLN-treated dog group, whereas in the
placebo control group, the maximal increase in EDA was
noted at Week 4. As a result, the interaction of treatment
on the temporal evolution of EDA recording demonstrated
at r e n d( P = 0.07) without denoting group effect.
According to the video-automated analysis, there was a
significant increase in the relative frequencies of two
major body position behaviours suggestive of comfort for
TLN dogs: Full weight bearing while standing with head
down increased by a factor of 2.92 (P = 0.03); Full weight
bearing while standing and looking around increased by
a factor of 7.7 (P = 0.03). Similarly, two motor activities
(gait) were also more frequently observed in this group:
Normal walking, factor of 5.22 (P =0 . 0 1 ) ;a n dn o r m a l
trotting, factor of 6.34 (P = 0.01).
The telemetered recording of DATI and DAAI
denoted higher movement in TLN dogs following sur-
gery (Table 1). Conversely, placebo control dogs were
less active than at baseline. This divergence led to the
discernment of an interaction (P =0 . 0 4 ,D A T Ia n d
DAAI) of treatment on the temporal evolution of tele-
metered actimetry, which resulted in higher DATI
recording in TLN dogs when compared to placebo con-
trol at Week 4 (P = 0.05).
Synovial fluid
The amount of joint effusion in the TLN-treated dogs
(6.7 (2.8) mL) was significantly less (P = 0.01) than that
found in the placebo control dogs (15.0 (7.6) mL). The
TLN-treated dogs also had lower levels of PGE2 (P =
0.02) (4.4 (3.6) ng/knee) and NOx (P = 0.01) (306.2
(267.1) nmol/knee) than those treated with placebo
(11.7 (7.2) ng/knee, and 766.28 (379.0) nmol/knee,
respectively).
Table 1 Pain and functional outcomes before and after anterior cruciate ligament transection in dogs
Time
Evaluation methods/Groups Baseline Week 4 Week 8 P-values
Function - kinetic gait analysis (%BW)
Placebo-control 71.4 (3.7) 27 (11.0) 32.2 (12.4) *<0.01
Tiludronate 73.6 (6.1) 35.1 (15.5) 43.6 (9.0) § = 0.05
¶ <0.01
Pain - Visual analog scale (VAS, measurement)
Placebo-control 0.0 (0.0) 37.6 (14.3) 26.8 (11.1) *<0.01
Tiludronate 0.0 (0.0) 26.9 (18.9) 15.6 (9.2)
Pain - Numerical rating scale (NRS, score)
Placebo-control 0.0 (0.0) 19.4 (4.3) 18.3 (3.7)
Tiludronate 0.0 (0.0) 15.5 (5.4) 15.0 (3.4) § = 0.03
Pain - Electrodermal activity (EDA, reading)
Placebo-control 4.5 (2.5) 6.4 (2.5) 5.3 (2.4)
Tiludronate 4.2 (2.7) 3.6 (2.5) 3.9 (2.4)
Function - Telemetered actimetry recording (count)
Daily averaged total intensity (DATI, no unit)
Placebo-control 97.9 (41.4) 79.1 (22.7) 85.7 (35.8)
Tiludronate 82.3 (25.4) 104.5 (44.6) 91.2 (33.1) ¶ = 0.04
Daily averaged active intensity (DAAI, no unit)
Placebo-control 390.9 (101.3) 360.6 (73.9) 379.1 (127.1)
Tiludronate 390.2 (82.9) 502.6 (145.7) 443.1 (117.1) ¶ = 0.04
Tiludronate was injected subcutaneously at 2 mg/kg, starting immediately on the day of ACL transection and repeated every two weeks for an eight-week
follow-up. Placebo-control dogs received mannitol injection in a similar fashion.
Data presented are mean (SD).
Statistically significant Time effect (*), Group effect (§) and Time per Group interaction (¶)
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Macroscopy
The severity of macroscopic lesions (depth and lesion
surface) on the femoral condyles and tibial plateaus of
TLN-treated dogs was not different from that observed
in placebo control dogs (data not shown). The size of
the osteophytes was similar between groups, both on
medial (TLN; 6.7 (2.6) mm, placebo control; 7.0 (1.9)
mm) and lateral (TLN; 6.5 (1.4) mm, placebo control;
7.1 (2.1) mm) condyles.
Histology
Histological grading of cartilage lesions did not reveal
significant difference between groups. The synovial
membrane score of TLN dogs (total score of 6.8 (1.1))
was similar to the placebo control dogs (total score of
6.1 (1.1)). The subset analyses revealed that the synovial
lining cell score was significantly (P < 0.01) less in TLN
dogs (1.0 (0.0)) compared to placebo control (1.7 (0.6)).
Immunohistochemistry
The cartilage immunohistochemistry revealed a signifi-
cant decrease in the percentage of cells staining positive
in TLN-treated dogs compared to the placebo control
(Figure 3) for MMP-13 (14.9 (2.5)% vs. 20.9 (4.2)%; P =
0.02) and ADAMTS5 (16.9 (2.3)% vs. 22.2 (4.2)%; P =
0.02). The level of MMP-1 was similar in both groups
(data not shown). Immunohistochemical analysis of the
calcified cartilage revealed a slight decrease in the level
of MMP-13 in TLN-treated dogs (19.7 (5.9)%) compared
to control dogs (22.4 (2.3)%, NS). In the subchondral
bone, the cathepsin K expression was significantly lower
in dogs that had received TLN compared to placebo
(1.9 (0.6) vs. 2.7 (0.8), P = 0.02) (Figure 3).
Histomorphometry
The surface of the calcified cartilage demonstrated a
trend (P = 0.07) to be greater in the TLN-treated dogs
compared to the placebo dogs (Table 2, Figure 4). Dogs
treated with TLN also had a significantly greater (P <
0.01) subchondral bone surface and smaller trabecular
separation compared to control dogs. Trabecular thick-
ness was similar in both treatment groups. The values
for TLN-treated dogs were similar to those previously
reported for normal dogs [6].
Discussion
Studies in the dog ACL model have provided insight
into OA mechanisms and pathophysiological pathways
that surround the evolution of the degenerative process.
The model was proven to be most useful at the preclini-
cal stage of drug development for testing the abilities of
new therapeutic modalities to limit or halt the disease
development/progression [5]. In the present study, TLN
was demonstrated to have a positive effect both on
some of the structural changes and on pain/function.
More particularly, TLN was found to decrease the pro-
duction of catabolic enzymes, bone resorption, and
synovial inflammation. These were associated with
improved locomotion, reduced lameness and gait dis-
ability, and improved joint pain perception. These find-
ings are in line with the report on a rat model of OA
[12] showing that the analgesic effect of the nitrogenous
BP zoledronate is mediated by its anti-resorptive action.
In the current study, TLN promoted better function
despite the presence of cartilage lesions, which were of
similar extent in OA and control dogs. This finding sug-
gests that cartilage integrity in a weight-bearing joint is
not compulsory for functional improvement. Further-
m o r e ,e v e nw h e nt h ek n e ej o i n tw a se x p o s e dt oa d d i -
tional mechanical constrains related to an increase in
limb support (that is, pain-relief), cartilage did not
undergo excessive alteration and remained similar to
control dogs.
This study demonstrated that TLN improves the func-
tional disability following ACL transection, more specifi-
cally the limb impairment, allowing dogs to load their
afflicted limb to a greater extent as demonstrated by the
results of the PVF analysis. Dogs were also more active
without showing evidence of severe lameness. The
stress/pain sensation was also reduced by TLN treat-
ment, as highlighted by the results of the EDA measure-
ments, pain scoring and behaviours denoting changes in
pain-related condition. Lameness improvement was
found to be maximal at Week 8 (PVF, NRS and video-
automated analysis of body position and motor activ-
ities), after dogs had received full TLN treatment. How-
ever, at the intermediate time-point (Week 4), the
difference between TLN and placebo groups was greater
than at Week 8 for both EDA and telemetered actime-
try. The beneficial effect of TLN therapy on pain/func-
tion was likely related to a combination of effects
including its anti-inflammatory effect shown by a reduc-
tion in synovial effusion size, synovitis score, and level
of inflammatory mediators, as well as its effect on the
initiation of bone remodelling [12].
Transduction of noxious signals occurs through high-
threshold receptors responding to a variety of thermal,
chemical and mechanical stimuli, and defined as poly-
modal nociceptors. At the level of damage-sensing neu-
rons, release of protons and high concentrations of
adenosine triphosphate (ATP) act, respectively, on tran-
sient receptor potential (TRP) and acid-sensing (ASIC)
ion channels, and on ionotropic ligand-gated purinergic
(P2X) receptors to activate nociceptors [38]. During the
early stages of inflammation, mediators such as PGs and
bradykinin change the sensitivity of receptors and
reduce the activation threshold for these conducting ion
channels, which is the basis for peripheral sensitization.
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Figure 3 Immunohistochemistry.( A) Expression of matrix metalloproteinase 13 (MMP-13), ADAMTS5 and cathepsin K in representative sections
of cartilage (MMP-13 and ADAMTS5) and subchondral bone (cathepsin K) from placebo-treated dogs with osteoarthritis (OA) and tiludronic acid
(TA: 2 mg/kg/2 weeks)-treated dogs with OA. Positive cells are shown by dark brown staining (original magnification ×100). (B) Levels of MMP-
13, ADAMTS5 and cathepsin K as determined by immunostaining. The values are expressed as the mean ± SEM. P-values were calculated by
using a generalized linear model under logistic polytomous distribution function using the proportional odds assumption.
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ity of TLN to reduce the inflammatory changes in the
OA synovium. Hence, TLN demonstrated a clear anti-
inflammatory local effect while decreasing the joint effu-
sion and synovitis (synovial lining cells). The analyses of
synovial fluid confirmed the anti-inflammatory effects
reflected by a decrease in the levels of PGE2 and NOx,
two well-known inflammatory mediators [39]. Inflam-
matory markers such as PGE2 are known to be corre-
lated with pain and functional disability in human OA
[40] as well as in the canine ACL model of OA [41].
The high level of synovial fluid NOx found in this study
is in line with our previous findings in this OA model,
in which the inducible NOS was found to be increased
[16,34]. It is likely that NO contributed to the disability
and perception of pain [42]. Moreover, the decrease in
NOx levels by TLN treatment may have contributed to
the structural protective effect of the drug as previously
demonstrated in this OA model [16]. Tiludronate, by
inhibiting the ATP-dependent proton pumps located in
the plasma membranes of the osteoclasts [43], can
reduce the acidification of the bone matrix, which is the
first step in the bone resorption process. In addition,
TLN can disrupt adhesion of the osteoclast to the bone
surface before bone resorption is initiated by modifying
the phosphorylation of proteins of the cytoskeleton [44].
As well as decreasing pro-inflammatory cytotrafficking
(cytokines and NO synthesis) [10], acidification and
phosphorylation and, in consequence, activation of pro-
teolytic enzymes, TLN can also inhibit activity of MMPs
[45]. In the present study, TLN was found to decrease
the expression of MMP-13 and ADAMTS5 in the carti-
lage and cathepsin K in the subchondral bone, which is
in line with the findings of our previous study [6] and
supports this hypothesis. The anti-inflammatory effects
of TLN are interesting, as they add to the most impor-
tant recognized biological effect of BPs, that is, the
reduction in bone remodelling through the inhibition of
osteoclastic activity. The pain and functional improve-
ments observed under TLN therapy were present at
Week 4 and maintained at Week 8. Therefore, it could
be hypothesized that the actions of TLN on bone matrix
and synovial inflammation would lead to a decrease in
TRPV1, ASIC3, and P2X receptors activation, translating
into diminished peripheral sensitization and subsequent
benefits on pain sensation and mobility. Although BPs
were developed for the treatment of pathologies asso-
ciated with excessive bone resorption, several reports
revealed that they were able to reduce the pain asso-
ciated with different painful diseases. Direct analgesic
Placebo - Control Tiludronate 2 mg/kg
Cartilage
Calcified 
cartilage
Subchondral
bone
Figure 4 Histomorphometry. Representative histological sections of calcified cartilage and subchondral bone in osteoarthritic dogs that
received either placebo (n = 8) or treatment with tiludronate (n = 8) 2 mg/kg/2 weeks. Specimens were selected from lesional areas of the tibial
plateaus (Fast green/Safranin O staining, original magnification ×63).
Table 2 Histomorphometry data eight weeks after anterior cruciate ligament transection in dogs
Calcified cartilage surface (10
-2
mm
2)
Subchondral bone surface (10
-2
mm
2)
Trabecular thickness (10
-2
mm)
Trabecular separation (10
-3
mm)
Placebo-
control
16.9 (3.9) 75.1 (9.3) 8.9 (2.3) 86.0 (52.6)
Tiludronate 19.8 (2.3) 86.2 (5.1)* 10.3 (2.0) 45.5 (15.1)*
Tiludronate was injected subcutaneously at 2 mg/kg, starting immediately on the day of ACL transection and repeated every two weeks for an eight-week
follow-up. Osteoarthritic placebo-treated dogs received mannitol injection in a similar fashion.
Data presented are mean (SD). * Statistically significant (P < 0.01) compared to placebo-control.
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reflex algesimetric tests in mice after acute administra-
tion [46]. Clodronate and pamidronate presented anti-
nociceptive dose-responses, comparing favourably to
aspirin and morphine, and the central and peripheral
analgesia did not appear to be mediated through opioid
receptors [46]. Prolonged anti-nociceptive effects have
also been demonstrated for clodronate, a non-nitrogen-
ous BP, without inducing any behavioural side effects
[47]. Such action has been proposed to explain the effi-
cacy of zoledronate in experimental rat OA models [12].
Increased osteoclastic activity, as found in OA
[4,13,17,18], could contribute to neuronal excitation and
pain, and, therefore, inhibition of bone resorption and
of nociceptor activation through anti-acid, anti-inflam-
matory actions would be analgesic. This hypothesis
maintains an interaction of TLN with the molecular
subchondral bone/cartilage cross-talk.
Subchondral bone mineral density decreases as early as
one month following ACL transection [48]. In this OA
model, extensive remodelling leading to a reduction in
subchondral bone plate thickness, bone surface, and tra-
becular thickness, increased trabecular separation and
loss of bone density and anisotropic properties were also
reported [6,49-51]. In this study, we found that following
TLN treatment a number of those changes were reduced
and closer to the values found in normal dogs [6]. More
specifically, the architecture of subchondral bone and cal-
cified cartilage was better preserved. The anti-resorptive
action of TLN may explain these findings.
The advance movement and duplication of the tidemark
contributes to overall thinning of the articular cartilage,
thickening of the calcified cartilage while altering the bio-
mechanic of the joint [18,52]. In ACL-deficient dogs, the
calcified cartilage undergoes thinning and an advancement
of the tidemark later in the OA process [6,48]. However,
duplication of the tidemark was previously reported fol-
lowing 12 weeks of BP treatment [21]. Whether or not
TLN affects the endochondral ossification remains to be
determined as change in the calcification front was not
assessed in the present study.
The decrease in cathepsin K activity observed under
TLN treatment is well in line with the known mode of
action of the drug at reducing osteoclastic activity
[9,10]. Given that mechanical loading governs bone
architecture and mass, the greater alteration in bone
structure found in placebo-treated dogs may also be
explained by the lower forces transmitted to the joint as
a consequence of pain-related limb disuse. Whereas pre-
vious studies using BPs [14,15] or other antiresorptive
agents [5-7] focused on the beneficial structural effects
in experimental OA models, the present study highlights
that the anti-resorptive effect of TLN was associated
with an apparent absence of effect on cartilage lesions,
but translated to beneficial analgesic and functional con-
sequences. One must, however, take into account that
the present study lasted only eight weeks, which is an
obvious limiting factor regarding the exploration of the
chondroprotective effect of TLN.
A recent analysis using MRI confirmed the common
belief that it is likely that changes in the subchondral
bone (BML) predominate in relation to OA knee pain
[2,53]. Bone marrow lesions are also associated with car-
tilage lesions [54]. These results support the dynamics of
bone/cartilage cross-talk, and the fact that TLN affected
the molecular, nociceptive, and biomechanical bone/car-
tilage interface in the canine ACL model. In the dog
ACL model, we have observed similar relationships
between MRI structural and functional changes
[22,23,55]. Such findings further support the transla-
tional nature of results obtained in the ACL dog model
to human OA.
Conclusions
The use of the dog ACL model in association with the
complete set of functional methods used in the present
study represents a most useful tool for the monitoring
of pain and joint function in OA. The present study
brings into perspective a possible link between joint
structural changes and functional outcomes. The level
of joint inflammation is an important co-factor in gener-
ating pain-related functional disability. The preservation
of bone integrity also likely plays a key role in functional
outcome, being required to reduce the disability occur-
ring in ACL-deficient dogs. This is supported by the
fact that TLN treatment demonstrated a positive effect
on gait disability and joint symptoms, while being asso-
ciated with a better preservation of calcified cartilage
and subchondral bone histomorphometry, as well as
reducing the synthesis of catabolic and inflammatory
mediators.
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